ROCK Inhibitor
-
Chloroxoquinoline
0 ImagesCat. No.: HY-W110138CAS No.: 23833-97-8Chloroxoquinoline is an anticancer agent. Chloroxoquinoline damages the DNA templates of cancer cells, inducing DNA breaks and cell death, and inhibits cell invasion via down-regulating Rho/Rho kinase signaling pathway. Chloroxoquinoline enhances the radiation sensitivity of Lewis lung cancer cells and xenograft tumors in tumor-bearing mouse models but decreases efficacy after long term exposure in rat models by auto-induction effects on CYP1A and CYP3A. Chloroxoquinoline has a broad-spectrum anticancer activity, such as non-small-cell lung carcinoma (NSCLC), breast cancer and gastric cancer.
-
ROCK-IN-9
0 ImagesCat. No.: HY-156593CAS No.: 2643334-76-1ROCK-IN-9 (Compound T345) is a ROCK inhibitor. ROCK-IN-9 shows cytotoxicity in HepG2 cell, with an IC50 of 40.8 μM. ROCK-IN-9 has good pharmacokinetic properties in mice, and shows high in vivo exposure and oral bioavailability at lower doses.
-
ROCK2-IN-15
0 ImagesCat. No.: HY-185667CAS No.: 3060005-08-2ROCK2-IN-15 (2-11) is a ROCK2 inhibitor with selective activity against Rho-kinase mediated phosphorylation of myosin light chain phosphates .ROCK2-IN-15 can be used for the research of cardiovascular diseases, pulmonary diseases, inflammatory diseases, neurological diseases, proliferative diseases .
-
ROCK-IN-10
0 ImagesCat. No.: HY-10833CAS No.: 1038549-25-5ROCK-IN-10 (compound 50) is a potent ROCK inhibitor with IC50 values of 6 nM and 4 nM for ROCK1 and ROCK2, respectively. ROCK-IN-10 shows >100-fold selectivity against other kinases.
-
ROCK2-IN-13
0 ImagesCat. No.: HY-179498ROCK2-IN-13 is a selective ROCK2 inhibitor. ROCK2-IN-13 reduces nuclear expression by disrupting the interaction of ROCK2 with transcriptional co activators p300> and PGC 1α, repressing oncogenic transcription. ROCK2-IN-13 activates FOXO1 driven PTEN expression, leading to suppression of the PI3K/Akt pathway, induction of G2/M cell cycle arrest, and promotion of apoptosis. ROCK2-IN-13 ablates the nuclear transcriptional function of ROCK2 that sustains oncogenic signaling and restores the tumor suppressive PTEN/FOXO1 axis. ROCK2-IN-13 can be used for prostate cancer reseach.
-
SB772077B
0 ImagesCat. No.: HY-123958CAS No.: 785774-34-7SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research.
-
ROCK2-IN-19
0 ImagesCat. No.: HY-189083ROCK2-IN-19, the non-isotopic form of compound 22d, is an orally active and selective ROCK2 inhibitor with an IC50 value of 13 nM. ROCK2-IN-19 selectively inhibits the phosphorylation of STAT3 at tyrosine 705, and suppresses breast cancer metastasis by disrupting the ROCK2-STAT3 signaling axis. ROCK2-IN-19 exhibits anti-metastatic activity in both cancer cells and xenograft models. ROCK2-IN-19 can be used in breast cancer-related research.
-
HA-100 hydrochloride
0 ImagesCat. No.: HY-100984ACAS No.: 141543-63-7
-
SR-3677 dihydrochloride
0 ImagesCat. No.: HY-13300ACAS No.: 1781628-88-3SR-3677 dihydrochloride (compound 5) is a potent and selective ROCK-I and ROCK-II inhibitor with an IC50 values of 56 nM and 3 nM.
-
AR-13503 (Standard)
0 ImagesCat. No.: HY-12798CRCAS No.: 2309668-15-1Synonyms: AR-13324 M1 metabolite (Standard)Fluanisone (Standard) is the analytical standard of Fluanisone. This product is intended for research and analytical applications. Fluanisone has potent sedative effect in vivo. Fluanisone can be used to study schizophrenia.
-
ROCK-IN-D1
0 ImagesCat. No.: HY-123484CAS No.: 1219721-73-9ROCK-IN-D1 serves as a highly effective and selective inhibitor of ROCK.
-
ROCK2-IN-5
0 ImagesCat. No.: HY-145294CAS No.: 3031515-48-4ROCK2-IN-5 (compound 1d) is a hybrid compound containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 has good multitarget profile and good tolerability. ROCK2-IN-5 has the potential for thr research of Amyotrophic lateral sclerosis (ALS) with a SOD1 mutation.
-
(Rac)-NRL-1049 dihydrochloride
0 ImagesCat. No.: HY-162596ACAS No.: 863638-93-1Synonyms: (Rac)-BA-1049(Rac)-NRL-1049 is the racemic mixture of NRL-1049 (BA-1049 (free base)) (HY-162596). NRL-1049 is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations.
-
Bazipsudil
0 ImagesCat. No.: HY-187858CAS No.: 2292312-76-4Bazipsudil is a potent, selective Rho-associated protein kinase (ROCK) inhibitor.
-
CCG-232964
0 ImagesCat. No.: HY-130011CAS No.: 2349373-70-0CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression.
-
5-Nitro-1H-indazole-3-carbonitrile
0 ImagesCat. No.: HY-W047432CAS No.: 90348-29-1Synonyms: DL08055-Nitro-1H-indazole-3-carbonitrile (DL0805) is a Rho kinase(ROCK) inhibitor with an IC50 of 6.67 μM for ROCK-I. 5-Nitro-1H-indazole-3-carbonitrile reduces Norepinephrine (HY-13715)-induced transient contraction and inhibits contraction induced by increasing external calcium in the endothelium-denuded rings of rat models. 5-Nitro-1H-indazole-3-carbonitrile has a vasorelaxant activity but high toxicity. 5-Nitro-1H-indazole-3-carbonitrile can be used for cardiovascular diseases, especially hypertension research.
-
LASSBio-2389
0 ImagesCat. No.: HY-181583CAS No.: 2671377-38-9LASSBio-2389 is a selective ROCK2 inhibitor with an IC50 of 0.051 μM and an IC50 of 1.143 μM against ROCK1. LASSBio-2389 reduces the viability of MDA-MB-231 cells and inhibits cell migration. LASSBio-2389 is applicable to the research of triple-negative breast cancer.
-
HA-100 dihydrochloride
0 ImagesCat. No.: HY-12880CAS No.: 210297-47-5
-
WF-536
0 ImagesCat. No.: HY-118837CAS No.: 539857-64-2
